glp 1 va study A Clinic Gave Veterans GLP-1s for Weight Loss. A Year Later, Everything Improved Large Analysis of Veterans With

Digestive health symptoms are the #1 barrier to GLP-1 adherence

Mendelsohn lays out why Vivani shifted from a broad platform story to focusing 90% of the company on a GLP-1 drugdevice product, how theyre using the 505(b)(2) pathway to shorten development by leveraging existing semaglutide data, and why the ability to stop treatment by removing the implant addresses a limitation of long-acting injectables

Take as directed by your healthcare professional, ideally as part of a comprehensive nutrition and lifestyle plan

Innovation in dosing convenience is also a notable trend, with companies developing once-monthly injection formulations and exploring oral GLP-1 receptor agonists, which could revolutionize treatment adherence and patient experience

Trulicity (dulaglutide) is not associated with an increased risk of urinary tract infections (UTIs) based on current evidence